1. Introduction {#sec0005}
===============

Acute respiratory tract infections (ARI) are a major cause of morbidity and mortality in a world in which viral etiologies predominate [@bib0005], [@bib0010]. Despite improved diagnostic techniques, the pathogen remained unidentified in a significant proportion of cases, which led to the search for new viruses [@bib0015]. Among these, human metapneumovirus (hMPV) was first isolated by genetic analysis of nasopharyngeal samples from 28 hospitalized children. In these children, this virus, which belongs to the Paramyxoviridae family, was associated with signs of airway infection: cough, fever, runny nose, wheezing and dyspnea [@bib0020]. hMPV is an enveloped virus with a single negative-stranded RNA genome of ∼13 kb [@bib0025]. As with other pneumoviruses, eight transcription units have been described. Some genes (F for the fusion protein, N for the nucleocapsid, M for the matrix and L for the polymerase) allow the characterization of the virus by reverse transcriptase polymerase chain reaction (RT- PCR) [@bib0030]. More recently, immunofluorescence [@bib0035], [@bib0040] and multiplex real-time PCR techniques have been developed and virological diagnosis is more feasible in clinical practice.

Though hMPV infection was identified in 2001, many of its features remain to be determined. Among the many research topics, the question of the prevalence of hMPV infections among ARI has been raised by many observational studies on various types of inpatient populations. To our knowledge, no synthesis of the available data concerning the role of hMPV in patients hospitalized with ARI has been done.

The purpose of this meta-analysis was to estimate the prevalence of hMPV infections in patients hospitalized for ARI and to study factors associated with this prevalence.

2. Methods {#sec0010}
==========

2.1. Data sources {#sec0015}
-----------------

Medline and ScienceDirect databases were searched for studies published from the inception of each database until December 27, 2014, without restriction on language. The following keywords were used: (1) in Pubmed: (metapneumovirus \[mesh\] OR metapneumovirus\[title/abstract\]) AND (hospital\[title/abstract\] OR hospitalized\[title/abstract\]) NOT ("Disease Outbreaks"\[Mesh\] OR "Outbreak"\[ti\]) NOT("Retrospective Studies"\[Mesh\] OR retrospective\[title/abstract\]); and (2) in ScienceDirect: TITLE-ABSTR-KEY(metapneumovirus) AND (TITLE-ABSTR-KEY(hospital) OR TITLE-ABSTR-KEY(hospitalized)) AND NOT TITLE(outbreak) AND NOT TITLE-ABSTR-KEY(retrospective). The titles and abstracts of potentially relevant studies were scanned. When the studies seemed to meet the eligibility criteria; or when the information was insufficient to exclude them; the full articles were read.

Articles dealing with literature reviews or meta-analyses were scanned for additional studies.

2.2. Inclusion and exclusion criteria {#sec0020}
-------------------------------------

Only prospective observational studies dealing with hospitalized patients with a clinical diagnosis of ARI were included. All types of ARI (upper, lower, pneumonia, severe pneumonia, bronchiolitis...) were included. Only studies including fever alone in the inclusion criteria were excluded. The search for hMPV had to be conducted systematically or by sampling of the population in the presence of defined inclusion criteria (respiratory signs) and by PCR (which is considered the gold standard) performed on respiratory samples.

Studies dealing with patients discharged after emergency admission, or which concerned a particular population (patients with cancer, cystic fibrosis, premature newborns, patients already hospitalized, patients screened for hMPV only if other respiratory viruses were negative, outbreak investigation), or with insufficiently detailed data to conduct a meta-analysis were excluded.

2.3. Data extraction and quality assessment {#sec0025}
-------------------------------------------

The data were extracted by two independent readers using a standardized grid and included: number of viruses screened, number of patients screened, number of patients infected with hMPV, viral and bacterial co-infections, inclusion periods, hospital location (country, city, continent, latitude, longitude), the gene used for the PCR, inclusion and exclusion criteria (patients' ages, definition of infection, severity), and the sampling method.

The study quality was evaluated by two independent readers using a standard form based on: (1) participation rate: more than 75% response (agree to participate) or analysis to show whether respondents and non-respondents were similar for the socio-demographic characteristics; (2) ARI correctly defined; (3) method of inclusion identical for all subjects; (4) description of diagnostic technique; (5) same type of sample collected for all patients (nasopharyngeal aspirate, nasal or throat swab...); (6) standardized method for sample collection (quantity of aspirate or of liquid used for the nasal wash...); (7) analysis performed according to relevant subgroups (by age classes, by center, or by symptomatology, for example); (8) presentation of data sources (counts are presented, not only percentages) [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065]. For each item, one point was awarded if the criterion was met. This resulted in a maximum score of 8. If the risk of non-response bias was uncertain, half a point was attributed.

2.4. Statistical analyses {#sec0030}
-------------------------

The prevalence of hMPV infections was calculated in a meta-analysis of the proportion of patients with a positive PCR for hMPV divided by the number of patients admitted for ARI. An arcsine transformation was used to stabilize the variation of proportions [@bib0070]. A random effect model was used according to DerSimonian-Laird's method [@bib0075]. Sensitivity analyses were conducted by removing the lower quality studies: in the first step, we removed studies for which we were not sure that the sample was systematically taken in the presence of the inclusion criteria. In the second step, the remaining studies with a quality score lower than six were excluded. Funnel plots and a rank test with calculation of Kendall's tau were used to highlight a publication bias [@bib0080].

Univariate meta-regressions were used to test for an effect of the publication year, the median year of inclusion, the continent, the hemisphere, the latitude, the absolute latitude (to reflect the distance from the equator), the longitude, the inclusion or not of chronic diseases (cardiac, pulmonary, immunodepression...), the inclusion of the first episode only, the sampling method (nasal wash, nasal swab...), the inclusion criteria (wheezing, ARI, pneumonia or other), the age category, and the inclusion period (complete year(s), less than 6 months corresponding to an epidemic period, more than 1 year with different numbers of months according to the year, and other: between 7 and 11 months).

Sub-group analyses were performed: (1) keeping only pediatric populations, (2) by inclusion criteria, and (3) for variables significant in multivariate analysis.

A *P* value of less than 0.20 in univariate analyses led to inclusion of the variable in multivariate models. For categorical variables, the global *P* value was considered for the inclusion in multivariate models. A *P* value of less than 0.05 was considered significant in multivariate analyses. Only variables that were significant in the multivariate model were kept in the multivariate final model. Analyses were performed with R [@bib0085] ("meta" [@bib0090] and "metafor" [@bib0095] packages).

3. Results {#sec0035}
==========

A total of 339 articles were obtained through the bibliographic search. Among these, 79 studies were retained ([Fig. 1](#fig0005){ref-type="fig"} ) [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160], [@bib0165], [@bib0170], [@bib0175], [@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210], [@bib0215], [@bib0220], [@bib0225], [@bib0230], [@bib0235], [@bib0240], [@bib0245], [@bib0250], [@bib0255], [@bib0260], [@bib0265], [@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290], [@bib0295], [@bib0300], [@bib0305], [@bib0310], [@bib0315], [@bib0320], [@bib0325], [@bib0330], [@bib0335], [@bib0340], [@bib0345], [@bib0350], [@bib0355], [@bib0360], [@bib0365], [@bib0370], [@bib0375], [@bib0380], [@bib0385], [@bib0390], [@bib0395], [@bib0400], [@bib0405], [@bib0410], [@bib0415], [@bib0420], [@bib0425], [@bib0430], [@bib0435], [@bib0440], [@bib0445], [@bib0450], [@bib0455], [@bib0460], [@bib0465], [@bib0470], [@bib0475], [@bib0480], [@bib0485], [@bib0490]. A recent meta-analysis of four respiratory viruses (not including hMPV) in acute lower respiratory infections in hospitalized children under five years of age was found [@bib0495]. One study with a search for hMPV was not retrieved with our bibliographic search strategy but was recovered from the manual search of this meta-analysis [@bib0500].Fig. 1Flow chart showing the study selection process.Fig. 1

3.1. Description of included studies {#sec0040}
------------------------------------

Most studies were conducted in Asia (36 studies) ([Table 1](#tbl0005){ref-type="table"} , [Fig. 2](#fig0010){ref-type="fig"} , Supplementary Table 1). Among the others, 23 were conducted in Europe, 11 in Africa, 5 in South America, 4 in North America, and 1 in Oceania.Table 1Description of context and methods of included studies.Table 1VariableNumber (n = 80)Proportion (%)ContinentAfrica1113.75North America45.00South America56.25Asia (+ Oceania: 1 study)3746.25Europe2328.75  Period of inclusionEpidemic with 6 months or less1316.25More than 6 months810.00Complete year(s)2531.25Period varying according to the year3442.50  Sample methodNasopharyngeal aspirate4556.25Nasal or throat swab1721.25Nasal wash911.25Bronchoalveolar lavage or several methods911.25  Inclusion criteria (type of acute respiratory infection)All acute respiratory infections3138.75Bronchiolitis/expiratory wheezing1620.00Bronchiolitis: inclusion if first episode only (n = 16)743.75Pneumonia1316.25Low respiratory infections2025.00Inclusion of severe forms only1113.75  Age0--3 years2936.250--18 years4558.25All ages45.00Adults only22.50Exclusion of chronic diseases1822.50Fig. 2Spatial distribution of the studies of human metapneumovirus among acute respiratory infections.Fig. 2

The size of the sample varied from 11 patients [@bib0425] to 28,369 [@bib0200], with a median of 320 (IQR 151.25--752.5). The inclusion period ranged from 3 months [@bib0305] to 5 years [@bib0200]. In most cases, the analyses were performed on nasopharyngeal or a nasal aspirates (45 studies). The N gene was most frequently used for the PCR primers. In most cases, the inclusion criterion was an ARI (including 31 studies with lower or upper respiratory tract infection and 20 studies with lower respiratory tract infection). Most studies included only pediatric populations (75 studies). Four studies included children and adults and two studies included adults only. Twenty-five studies were conducted in complete years, 34 over several years with varying inclusion periods depending on the year, 13 in one or several years but only during epidemic periods and 8 in one or several years during inclusion periods of seven to 11 months. Eleven studies included severe forms only, with various criteria for the definition of severity. The median quality score was 6.5 (IQR 5.5--7). The quality of studies is summarized in Supplementary Table 2, and details are shown in Supplementary Table 3.

Co-infections with other viruses were frequently observed (Supplementary Table 4).

3.2. Prevalence of hMPV among hospitalized ARI {#sec0045}
----------------------------------------------

The prevalence of hMPV among patients hospitalized with ARI varied from 0% (95% CI 0.0--2.7) [@bib0370] to 36.4% (95% CI 10.9--69.2) [@bib0425] (Supplementary Table 4). The estimated prevalence of hMPV among hospitalized ARI was 6.39 (95% CI 5.45--7.39). The heterogeneity was very high (I^2^  = 96.8%, 95% CI 96.4--97.1). Several studies were conducted in populations which could have been included in part in other studies [@bib0125], [@bib0140], [@bib0145], [@bib0175], [@bib0215], [@bib0220], [@bib0225], [@bib0230], [@bib0365], [@bib0390], [@bib0400], [@bib0450]. In choosing studies to keep in the quantitative analyses, we privileged the higher quality studies. This led to 75 studies, which included 82,240 patients ([Fig. 3](#fig0015){ref-type="fig"} ), with a pooled prevalence of hMPV among ARI of 6.24 (95% CI 5.25--7.30). The heterogeneity remained high (I^2^  = 96.6%, 95% CI 96.2--97.0).Fig. 3Forest plot of studies included in meta-analyses of prevalence of human metapneumovirus among hospitalized acute respiratory infections (n = 75). The dashed line represents the pooled prevalence (6.24%).Fig. 3

Sensitivity analyses led to consistent results. The prevalence of hMPV was 6.14% (95% CI 5.03--7.35) after the removal of 10 studies in which systematic inclusion was not sure and 6.26% (95% CI 5.29--7.31) after the removal of 6 other studies with a score of less than 6.

We found a higher prevalence of hMPV in small studies than in large studies ([Fig. 4](#fig0020){ref-type="fig"} ). The rank test confirmed the asymmetry of the funnel plot (p \< 0.001).Fig. 4Funnel plot of the meta-analysis of the prevalence of human metapneumovirus among hospitalized acute respiratory infections.Fig. 4

The cumulative meta-analysis, which included studies from the largest to the smallest, showed stabilization of the prevalence near to the 35th largest study (which included 336 patients) with a prevalence at around 6% ([Fig. 5](#fig0025){ref-type="fig"} ).Fig. 5Cumulative meta-analyses of the prevalence of human metapneumovirus (hMPV) among hospitalized acute respiratory infections from the largest to smallest studies, with 95% confidence intervals.Fig. 5

3.3. Factors associated with the prevalence of hMPV infections {#sec0050}
--------------------------------------------------------------

Univariate meta-regressions showed a higher prevalence when the inclusion period was 7--11 months per year (coefficient 0.096, *P*  = 0.023) or complete years (coefficient 0.047, *P*  = 0.100) than with epidemic periods of 6 months or less ([Table 2](#tbl0010){ref-type="table"} ). This variable was globally associated with the prevalence of hMPV infections (*P*  = 0.014). Other tested variables were not statistically associated with the prevalence of hMPV infections.Table 2Univariate and multivariate *meta*-regressions of the prevalence of human metapneumovirus infections in hospitalized acute respiratory infections (n = 75).Table 2Univariate analysisMultivariate analysisVariableCoefficient (95% CI)P valueCoefficient (95% CI)*P* valuePublication year−0.0045 (−0.0112; 0.0021)0.182  Continent (reference: Africa)[a](#tblfn0005){ref-type="table-fn"}North America0.0817 (−0.0241; 0.1874)0.130South America0.0642 (−0.0443; 0.1727)0.246Asia (+ Oceania: 1 study)0.0283 (−0.0372; 0.0938)0.397Europe0.0387 (−0.0321; 0.1095)0.284Latitude0.0002 (−0.0007; 0.0012)0.610Absolute latitude (reference: equator)0.0015 (−0.0003; 0.0033)0.1020.0017 (0.0001--0.0033)0.038Longitude−0.0001 (−0.0004; 0.0002)0.414  Period of inclusion (reference: epidemic with 6 months or less)[b](#tblfn0010){ref-type="table-fn"}More than 6 months0.0957 (0.0132; 0.1782)0.0230.1071 (0.0239; 0.1903)0.012Complete year(s)0.0474 (−0.0091; 0.1040)0.1000.0638 (0.0052; 0.1224)0.033Period varying according to the year−0.0027 (−0.0561; 0.0508)0.9210.0154 (−0.0407; 0.0715)0.592  Sample method (reference: nasopharyngeal aspirate)[a](#tblfn0005){ref-type="table-fn"}Nasal or throat swab−0.0140 (−0.0590; 0.0311)0.543Nasal wash0.0263 (−0.0322; 0.0847)0.378Bronchiolo-alveolar washing or several methods0.0084 (−0.0542; 0.0711)0.792Inclusion criteria (reference: all acute respiratory infections)[a](#tblfn0005){ref-type="table-fn"}Bronchiolitis/expiratory wheezing0.0199 (−0.0342; 0.0739)0.471  Pneumonia−0.0074 (−0.0644; 0.0496)0.799Low respiratory infections0.0337 (−0.0117; 0.0852)0.198Inclusion if first episode only−0.0206 (−0.0875; 0.0464)0.547Inclusion of severe forms only−0.0465 (−0.1073; 0.0143)0.134  Age: 4 categories (reference 0--3 years)[a](#tblfn0005){ref-type="table-fn"}0-18 years−0.0102 (−0.0534; 0.0331)0.646All ages−0.0631 (−0.1510; 0.0249)0.160Adults−0.0428 (−0.1683; 0.0827)0.504Age (adults or all ages versus children)−0.0504 (−0.1202; 0.0194)0.157Exclusion of chronic diseases−0.0102 (−0.0621; 0.0417)0.699Quality score−0.0010 (−0.0222; 0.0203)0.928Number of samples−4.3.106 (−8.9.106; 0.3.106)0.067[^1][^2]

In multivariate analyses, the positive association with the absolute latitude became significant. The association with the inclusion period was still highlighted with a global *P* value for the likelihood ratio test of 0.0114. We found no associations with disease severity, age of inclusion, the number of samples included or the year. Further adjustments for age at inclusion did not significantly change the results (not shown).

3.4. Subgroup meta-analyses {#sec0055}
---------------------------

In a subgroup analysis for pediatric patients (69 studies), the pooled prevalence was 6.40% (95% CI 5.51--7.35). Other subgroup analyses are shown in [Table 3](#tbl0015){ref-type="table"} .Table 3Subgroup analyses of the prevalence of human metapneumovirus infections in hospitalized acute respiratory infections (n = 75).Table 3SubgroupNumber of studiesPooled proportion95% CIInclusion criteriaAcute respiratory infection275.704.49--7.04Low acute respiratory infection187.444.99--10.32Bronchiolitis/expiratory wheezing176.454.82--8.30Pneumonia135.273.74--7.05  Period of inclusion6 months or less in a year135.364.29--6.547 to 11 months in a year710.565.97--16.27Complete years237.555.90--9.38More than one year with different periods according to the year325.123.95--6.44

4. Discussion {#sec0060}
=============

In our meta-analysis of 75 studies with globally good methodological quality, the estimated prevalence of hMPV infections among hospitalized ARI was 6.24% (95% CI 5.25--7.30), with high heterogeneity. Sensitivity analyses gave similar results. We observed an effect of the period of inclusion with a significantly higher prevalence of hMPV infections in studies conducted during periods of 7--11 months or complete years than in periods of 6 months or less, and a significant increase in incidence with increasing distance from the equator.

In a recent meta-analysis that included 21 studies, Wang et al. found a similar prevalence of hMPV in childhood community-acquired pneumonia (6.1, 95% CI 4.1--8.1) [@bib0505]. Concerning other viruses, influenza, parainfluenza and adenovirus were found in proportions similar to that for hMPV: 6.3, 7.8 and 6.0% of cases, respectively. Respiratory syncytial virus, rhinovirus and bocavirus were more frequently observed (17.5%, 18.9% and 12.7%, respectively). Coronavirus was less frequent (3.9%). Luksic et al. provided a meta-analysis of the viral etiology of hospitalized acute lower respiratory infections in children under five years [@bib0495]. The prevalence of influenza viruses, parainfluenza viruses, and adenoviruses was 3.0% (95% CI 2.2--4.0), 2·7 (95% CI 1.9--3.7), and 5.8% (95% CI 3.4%--9.1%), respectively. The prevalence of coronavirus could not be estimated. Other viruses were not studied. Nair et al. reported 22% of respiratory syncytial virus in acute low respiratory infections in children under five years [@bib0510]. In the studies included in our meta-analysis, co-infections with other respiratory viruses were frequently observed. The prevalence of ARI due to hMPV only would have been lower, which would have been the case for other respiratory viruses, but this prevalence could not be estimated due to the diversity of the other viruses screened for.

Only studies using PCR to detect hMPV in patients hospitalized with an ARI, excluding fever without any respiratory symptoms, were included to limit the heterogeneity. Nevertheless, a high degree of heterogeneity was observed (I^2^  = 96.8%, 95% CI 96.4-97.1). This could be due to the diversity of study characteristics. Although meta-regressions took several study characteristics into account (sampling method, type of period, inclusion criteria, continent, year...), these variables explained only a very small part of the heterogeneity encountered. This could be due to the heterogeneousness of the studies' characteristics persisting in each category. For example, inclusion criteria were classified in four categories (all ARI, low ARI, bronchiolitis or expiratory wheezing, and pneumonia), but "all ARI" or "low ARI" could be defined differently (or not defined in 19/45 cases) according to the study. For the above reasons, subgroup analysis according to the definition of ARI could not be performed. Furthermore, the difference in prevalences observed between studies could be due to the strains varying according to the year and the location, leading to epidemics of varying magnitude. Indeed, like influenza virus epidemics, hMPV epidemics have different magnitudes depending on the year, as shown in several studies conducted over several years [@bib0150], [@bib0200], [@bib0340], [@bib0420], [@bib0460], [@bib0515]. No linear effect of the year was observed. Non-linear effects were not tested because we hypothesized that the variations according to the year would be different from one country to another. Similar heterogeneity was found in other meta-analyses of respiratory viruses [@bib0495], [@bib0505], [@bib0510].

The prevalence of hMPV was higher in studies conducted during inclusion periods of 7--11 months or in complete year(s) than in studies conducted in periods of 6 months or less. These periods of 6 months or less probably corresponded to the epidemic period for ARI or influenza. However, they may not have corresponded to the epidemic period for hMPV. In several studies conducted in Europe or Asia during complete years, the epidemic peak occurred in March or April in Asia and February or March in Europe [@bib0160], [@bib0170], [@bib0200], [@bib0215], [@bib0245], [@bib0375], [@bib0490]. However, several other studies included patients between September-October and March-April, and these could have underestimated the prevalence of hMPV. In other studies, in particular in South and Central America (two studies in Brazil [@bib0365], [@bib0450], one study in Argentina [@bib0305] and one study in Guatemala [@bib0340]), hMPV infections occurred throughout the year, which was not the case for other respiratory viruses. Once again, studies conducted in epidemic periods of respiratory infections could have underestimated the prevalence of hMPV in ARI.

The prevalence of hMPV infections increased with distance from the equator. This could be due to the higher temperature and the seasonality of the climate, which is less pronounced near to the equator.

One of the strengths of this study is that it is the first meta-analysis about the prevalence of hMPV infections in hospitalized patients with ARI, and it included all ARI criteria in populations of all ages. We chose to include only hospitalized patients who were screened for hMPV using PCR, in prospective studies that included all patients (or random sampling of patients) in the presence of inclusion criteria to limit the heterogeneity and to improve the quality of data. A total of 80, mostly high-quality, studies were included in the qualitative analyses and 75 studies (which accounted for 82,240 patients) were included in the meta-analyses and meta-regressions. Retrospective studies were excluded to avoid the inclusion of studies in which hMPV was not systematically tested and to avoid other bias inherent to retrospective studies.

This study had some limitations. Firstly, a high degree of heterogeneity was observed and most of this heterogeneity could not be explained by the variables tested. All the characteristics of the study could not be taken into account because the information was not available. However, as mentioned above this heterogeneity probably reflects the reality of the prevalence of hMPV in ARI across countries and according to the year. Thus, the estimation of the worldwide prevalence of hMPV in ARI does not reflect the prevalence in every country in every year. Nonetheless, the observed heterogeneity is a result of interest. Secondly, a publication bias could be suspected from the funnel plot, the rank test, and the prevalence of hMPV, which decreased with the number of samples in univariate analysis. However, the cumulative meta-analysis from the largest to the smallest study showed stabilization of the prevalence at around 6% near the 35th largest study, and did not show a large increase with the smaller studies. Moreover, the asymmetry is probably due to the very high heterogeneity [@bib0520]. This is why we did not use methods such as trim-and-fill methods [@bib0525]. Thirdly, although the global quality of included studies was good, the definition of acute respiratory infection was not clear in many studies. Fourthly, the literature search strategy could be questionable and may have been restrictive, but 75 studies were included. Finally, despite the inclusion of all ages in our inclusion criteria, most of studies were conducted in pediatric populations. This study therefore mainly reflects the prevalence of hMPV in children.

In conclusion, hMPV should be taken into account as a possible etiology in hospitalized ARI. The prevalence of hMPV among ARI was 6.24% (95% CI 5.25--7.30). The heterogeneity was high (I^2^  = 96.6%, 95% CI 96.2--97.0) but the prevalence was stable over time. We observed a significantly higher prevalence of hMPV in studies conducted during periods of 7--11 months or complete years than in periods of 6 months or less and a significant increase in the incidence with increasing distance from the equator.
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[^1]: Global *P* value \<0.200.

[^2]: Global *P* value = 0.014 and 0.011 for univariate and multivariate analyses, respectively.
